Adhera Therapeutics, Inc. (ATRX) SEC Filing 10-Q Quarterly Report for the period ending Thursday, March 31, 2022

Adhera Therapeutics, Inc.

CIK: 737207 Ticker: ATRX
Cover - shares
3 Months Ended
Mar. 31, 2022
May 16, 2022
Cover [Abstract]  
Document Type10-Q 
Amendment Flagfalse 
Document Quarterly Reporttrue 
Document Transition Reportfalse 
Document Period End DateMar. 31, 2022 
Document Fiscal Period FocusQ1 
Document Fiscal Year Focus2022 
Current Fiscal Year End Date--12-31 
Entity File Number000-13789 
Entity Central Index Key0000737207 
Entity Tax Identification Number11-2658569 
Entity Incorporation, State or Country CodeDE 
Entity Address, Address Line One8000 Innovation Parkway 
Entity Address, City or TownBaton Rouge 
Entity Address, State or ProvinceLA 
Entity Address, Postal Zip Code70820 
City Area Code(919) 
Local Phone Number518-3748 
Entity Current Reporting StatusYes 
Entity Interactive Data CurrentYes 
Entity Filer CategoryNon-accelerated Filer 
Entity Small Businesstrue 
Entity Emerging Growth Companyfalse 
Entity Shell Companyfalse 
Entity Common Stock, Shares Outstanding 17,493,237

View differences made from one quarter to another to evaluate Adhera Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adhera Therapeutics, Inc..


Assess how Adhera Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Adhera Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows (Unaudited)
Consolidated Statements Of Operations (Unaudited)
Consolidated Statements Of Stockholders' Deficit
Commitments And Contingencies
Commitments And Contingencies (Details Narrative)
Licensing Agreements
Licensing Agreements (Details Narrative)
Notes Payable And Convertible Promissory Notes
Notes Payable And Convertible Promissory Notes (Details Narrative)
Notes Payable And Convertible Promissory Notes (Tables)
Organization And Business Operations
Prepaid Expenses
Prepaid Expenses (Details Narrative)
Related Party Transactions
Related Party Transactions (Details Narrative)
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share (Details)
Schedule Of Convertible Promissory Notes (Details)
Schedule Of Earnings Per Share, Basic And Diluted (Details)
Schedule Of Fair Value Measurements (Details)
Schedule Of Fair Value Of Derivative Liabilities Estimated Issuance And Valuation Mode (Details)
Schedule Of Roll Forward Of Level 3 Financial Instruments (Details)
Schedule Of Share Based Payment Arrangement, Option, Exercise Price Range (Details)
Schedule Of Share Based Payments Arrangement, Option Activity (Details)
Schedule Of Stockholders??? Equity Note, Warrants Or Rights (Details)
Schedule Of Warrants (Details)
Stock Incentive Plans
Stock Incentive Plans (Details Narrative)
Stock Incentive Plans (Tables)
Stockholders??? Equity
Stockholders??? Equity (Details Narrative)
Stockholders??? Equity (Tables)
Subsequent Events
Subsequent Events (Details Narrative)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details Narrative)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Ticker: ATRX
CIK: 737207
Form Type: 10-Q Quarterly Report
Accession Number: 0001493152-22-013775
Submitted to the SEC: Mon May 16 2022 4:07:27 PM EST
Accepted by the SEC: Mon May 16 2022
Period: Thursday, March 31, 2022
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: